Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy. Issue 8 (November 2020)

• Record Type: Journal Article
• Authors: Dhir, Aditi; Kelly, David R.; Watts, Raymond G.; Kutny, Matthew A.
• Is Part Of: Journal of pediatric hematology/oncology. Volume 42:Issue 8(2020)
• Publication Date: 2020-11
• Subjects: Langerhan cells -- nonsteroidal anti-inflammatory drug -- indomethacin monotherapy -- refractory histiocytosis; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000001474
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Langerhans cell histiocytosis (LCH) often has a recurrent and refractory course despite multiagent treatment modalities. Common relapse treatments include intense or prolonged cytotoxic chemotherapy regimens. There are a few prior reports that the nonsteroidal anti-inflammatory drug indomethacin demonstrated activity against bone LCH. Here we report indomethacin as a successful treatment for a case of chronic skin LCH that failed multiple prior chemotherapy regimens. This experience supports the need for trials to investigate indomethacin as a treatment for LCH both in the relapsed or refractory setting as well as potential combination or maintenance therapy in newly diagnosed patients.